Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/9718051/ below:

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

Clinical Trial

Affiliations

• ¹ University of California, San Francisco 94143, USA.

• PMID: 9718051
• DOI: 10.1001/jama.280.7.605

Item in Clipboard

Clinical Trial

S Hulley et al. JAMA. 1998.

• ¹ University of California, San Francisco 94143, USA.

• PMID: 9718051
• DOI: 10.1001/jama.280.7.605

Item in Clipboard

Context: Observational studies have found lower rates of coronary heart disease (CHD) in postmenopausal women who take estrogen than in women who do not, but this potential benefit has not been confirmed in clinical trials.

Objective: To determine if estrogen plus progestin therapy alters the risk for CHD events in postmenopausal women with established coronary disease.

Design: Randomized, blinded, placebo-controlled secondary prevention trial.

Setting: Outpatient and community settings at 20 US clinical centers.

Participants: A total of 2763 women with coronary disease, younger than 80 years, and postmenopausal with an intact uterus. Mean age was 66.7 years.

Intervention: Either 0.625 mg of conjugated equine estrogens plus 2.5 mg of medroxyprogesterone acetate in 1 tablet daily (n = 1380) or a placebo of identical appearance (n = 1383). Follow-up averaged 4.1 years; 82% of those assigned to hormone treatment were taking it at the end of 1 year, and 75% at the end of 3 years.

Main outcome measures: The primary outcome was the occurrence of nonfatal myocardial infarction (MI) or CHD death. Secondary cardiovascular outcomes included coronary revascularization, unstable angina, congestive heart failure, resuscitated cardiac arrest, stroke or transient ischemic attack, and peripheral arterial disease. All-cause mortality was also considered.

Results: Overall, there were no significant differences between groups in the primary outcome or in any of the secondary cardiovascular outcomes: 172 women in the hormone group and 176 women in the placebo group had MI or CHD death (relative hazard [RH], 0.99; 95% confidence interval [CI], 0.80-1.22). The lack of an overall effect occurred despite a net 11% lower low-density lipoprotein cholesterol level and 10% higher high-density lipoprotein cholesterol level in the hormone group compared with the placebo group (each P<.001). Within the overall null effect, there was a statistically significant time trend, with more CHD events in the hormone group than in the placebo group in year 1 and fewer in years 4 and 5. More women in the hormone group than in the placebo group experienced venous thromboembolic events (34 vs 12; RH, 2.89; 95% CI, 1.50-5.58) and gallbladder disease (84 vs 62; RH, 1.38; 95% CI, 1.00-1.92). There were no significant differences in several other end points for which power was limited, including fracture, cancer, and total mortality (131 vs 123 deaths; RH, 1.08; 95% CI, 0.84-1.38).

Conclusions: During an average follow-up of 4.1 years, treatment with oral conjugated equine estrogen plus medroxyprogesterone acetate did not reduce the overall rate of CHD events in postmenopausal women with established coronary disease. The treatment did increase the rate of thromboembolic events and gallbladder disease. Based on the finding of no overall cardiovascular benefit and a pattern of early increase in risk of CHD events, we do not recommend starting this treatment for the purpose of secondary prevention of CHD. However, given the favorable pattern of CHD events after several years of therapy, it could be appropriate for women already receiving this treatment to continue.

PubMed Disclaimer

• ACP J Club. 1999 Jan-Feb;130(1):8
• Hormone replacement therapy and heart disease prevention: experimentation trumps observation.

  Petitti DB. Petitti DB. JAMA. 1998 Aug 19;280(7):650-2. doi: 10.1001/jama.280.7.650. JAMA. 1998. PMID: 9718060 No abstract available.

• Hormone replacement therapy for secondary prevention of coronary heart disease.

  Pan CX, Boal J. Pan CX, et al. JAMA. 1999 Mar 3;281(9):794; author reply 796-7. JAMA. 1999. PMID: 10070993 No abstract available.

• Hormone replacement therapy for secondary prevention of coronary heart disease.

  Banks E, Beral V. Banks E, et al. JAMA. 1999 Mar 3;281(9):794; author reply 796-7. JAMA. 1999. PMID: 10070994 No abstract available.

• Hormone replacement therapy for secondary prevention of coronary heart disease.

  Ong PJ, Sorensen MB, Hayward CS, Webb CM, Collins P. Ong PJ, et al. JAMA. 1999 Mar 3;281(9):794-5; author reply 796-7. JAMA. 1999. PMID: 10070995 No abstract available.

• Hormone replacement therapy for secondary prevention of coronary heart disease.

  Sullivan JL. Sullivan JL. JAMA. 1999 Mar 3;281(9):795; author reply 796-7. JAMA. 1999. PMID: 10070996 No abstract available.

• Hormone replacement therapy for secondary prevention of coronary heart disease.

  Heckbert SR, Weiss NS, Psaty BM. Heckbert SR, et al. JAMA. 1999 Mar 3;281(9):795-6; author reply 796-7. JAMA. 1999. PMID: 10070997 No abstract available.

• Hormone replacement therapy for secondary prevention of coronary heart disease.

  Vandenbroucke JP. Vandenbroucke JP. JAMA. 1999 Mar 3;281(9):796; author reply 797. JAMA. 1999. PMID: 10070998 No abstract available.

• Estrogen for bone health in frail elderly women.

  Reed SB, Bellantoni MF. Reed SB, et al. JAMA. 2001 Nov 28;286(20):2544. doi: 10.1001/jama.286.20.2544. JAMA. 2001. PMID: 11722260 No abstract available.

• Prescriptions for estrogen replacement therapy in Ontario before and after publication of the Women's Health Initiative Study.

  Austin PC, Mamdani MM, Tu K, Jaakkimainen L. Austin PC, et al. JAMA. 2003 Jun 25;289(24):3241-2. doi: 10.1001/jama.289.24.3241. JAMA. 2003. PMID: 12824204 No abstract available.

• Postmenopausal hormone treatment.

  Hulley S, Grady D. Hulley S, et al. JAMA. 2009 Jun 17;301(23):2493-5. doi: 10.1001/jama.2009.847. JAMA. 2009. PMID: 19531791 No abstract available.

• Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).

  Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N; HERS Research Group. Grady D, et al. JAMA. 2002 Jul 3;288(1):49-57. doi: 10.1001/jama.288.1.49. JAMA. 2002. PMID: 12090862 Clinical Trial.

• Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

  Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators. Rossouw JE, et al. JAMA. 2002 Jul 17;288(3):321-33. doi: 10.1001/jama.288.3.321. JAMA. 2002. PMID: 12117397 Clinical Trial.

• Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause.

  Shlipak MG, Simon JA, Vittinghoff E, Lin F, Barrett-Connor E, Knopp RH, Levy RI, Hulley SB. Shlipak MG, et al. JAMA. 2000 Apr 12;283(14):1845-52. doi: 10.1001/jama.283.14.1845. JAMA. 2000. PMID: 10770146 Clinical Trial.

• The Heart and Estrogen/Progestin Replacement Study: what have we learned and what questions remain?

  Wells G, Herrington DM. Wells G, et al. Drugs Aging. 1999 Dec;15(6):419-22. doi: 10.2165/00002512-199915060-00001. Drugs Aging. 1999. PMID: 10641952 Review.

• Alternative hormone replacement regimens: is there a need for further clinical trials?

  Welty FK. Welty FK. Curr Opin Lipidol. 2003 Dec;14(6):585-91. doi: 10.1097/00041433-200312000-00006. Curr Opin Lipidol. 2003. PMID: 14624135 Review.

• Gender differences in non-ischemic myocardial remodeling: are they due to estrogen modulation of cardiac mast cells and/or membrane type 1 matrix metalloproteinase.

  Janicki JS, Spinale FG, Levick SP. Janicki JS, et al. Pflugers Arch. 2013 May;465(5):687-97. doi: 10.1007/s00424-013-1229-9. Epub 2013 Feb 16. Pflugers Arch. 2013. PMID: 23417570 Free PMC article. Review.

• Effect of menopausal hormone therapy on components of the metabolic syndrome.

  Lovre D, Lindsey SH, Mauvais-Jarvis F. Lovre D, et al. Ther Adv Cardiovasc Dis. 2016 May 27;11(1):33-43. doi: 10.1177/1753944716649358. Online ahead of print. Ther Adv Cardiovasc Dis. 2016. PMID: 27234158 Free PMC article. Review.

• Sex and Response to Cardioprotective Conditioning Maneuvers.

  Querio G, Geddo F, Antoniotti S, Gallo MP, Penna C. Querio G, et al. Front Physiol. 2021 May 14;12:667961. doi: 10.3389/fphys.2021.667961. eCollection 2021. Front Physiol. 2021. PMID: 34054579 Free PMC article. Review.

• The role of estrogens in control of energy balance and glucose homeostasis.

  Mauvais-Jarvis F, Clegg DJ, Hevener AL. Mauvais-Jarvis F, et al. Endocr Rev. 2013 Jun;34(3):309-38. doi: 10.1210/er.2012-1055. Epub 2013 Mar 4. Endocr Rev. 2013. PMID: 23460719 Free PMC article. Review.

• Pathological Importance of the Endothelin-1/ET(B) Receptor System on Vascular Diseases.

  Kitada K, Ohkita M, Matsumura Y. Kitada K, et al. Cardiol Res Pract. 2012;2012:731970. doi: 10.1155/2012/731970. Epub 2012 Jul 30. Cardiol Res Pract. 2012. PMID: 22900227 Free PMC article.

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3